Form 8-K

8-K — Celldex Therapeutics, Inc.

Accession: 0001104659-26-078023

Filed: 2026-06-26

Period: 2026-06-25

CIK: 0000744218

SIC: 2835 (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — tm2619009d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2619009d1_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2619009d1_8k.htm · Sequence: 1

false

0000744218

2026-06-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C.

20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 25, 2026

Celldex

Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

000-15006

13-3191702

(State

or other jurisdiction of incorporation)

(Commission

File Number)

(IRS

Employer Identification No.)

Perryville III Building, 53 Frontage Road, Suite 220,

Hampton,

New Jersey 08827

(Address of principal executive offices) (Zip

Code)

(908)

200-7500

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant

to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $.001

CLDX

Nasdaq

Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR

§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election

of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 25, 2026, at the 2026 Annual Meeting

of Stockholders (the “Annual Meeting”) of Celldex Therapeutics, Inc. (the “Company”), the Company’s

stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Omnibus Equity Incentive Plan (the “2021

Plan”) (i) increasing the number of shares available for issuance under the 2021 Plan by 3,400,000 shares and (ii) clarifying

the tax withholding provisions applicable to awards under the 2021 Plan. The Plan Amendment became effective following its approval by

the Company’s stockholders.

The foregoing description of the Plan Amendment

does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as

Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 25, 2026, at the Annual Meeting,

the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company’s definitive proxy

statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”).

The final results for the votes regarding each proposal are set forth below.

1. The stockholders elected

the following individuals to serve on the Company’s board of directors until the annual meeting of stockholders to be held in 2027.

The tabulation of votes with respect to the election of such directors was as follows:

Nominees

For

Against

Abstain

Broker Non-Votes

Harry H. Penner, Jr. (Chair of the Board)

59,455,265

1,047,261

181,190

4,402,319

Anthony S. Marucci (Chief Executive Officer)

60,218,830

282,968

181,918

4,402,319

Keith L. Brownlie

59,858,683

644,110

180,923

4,402,319

Cheryl L. Cohen

60,046,578

456,194

180,944

4,402,319

Herbert J. Conrad

59,524,978

975,608

183,130

4,402,319

Rita I. Jain, M.D.

59,495,870

1,000,240

187,606

4,402,319

James J. Marino

59,910,902

591,402

181,412

4,402,319

Garry A. Neil, M.D.

59,570,030

932,772

180,914

4,402,319

Denice Torres

60,135,775

366,304

181,637

4,402,319

2. The stockholders approved

the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm

for the year ending December 31, 2026. The tabulation of votes with respect to this proposal was as follows:

For

Against

Abstain

64,712,039

174,706

199,290

3. The stockholders approved

an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder

by 3,400,000 shares to 12,900,000 shares. The tabulation of votes with respect to this proposal was as follows:

For

Against

Abstain

Broker Non-Votes

58,844,414

1,654,297

185,005

4,402,319

4. The stockholders voted

to approve, on an advisory, non-binding basis, the compensation for the Company’s named executive officers as disclosed in the Proxy

Statement. The tabulation of votes with respect to this proposal was as follows:

For

Against

Abstain

Broker Non-Votes

59,258,619

945,414

479,683

4,402,319

-2-

Item 9.01. Financial Statements and Exhibits.

Exhibit No.

Description

10.1

Amendment No. 4 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

-3-

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELLDEX THERAPEUTICS, INC.

Dated: June 26, 2026

By:

/s/ Sam Martin

Name:

Sam Martin

Title:

Senior Vice President and Chief Financial Officer

-4-

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2619009d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

AMENDMENT No. 4 TO

CELLDEX THERAPEUTICS, INC.

2021 OMNIBUS EQUITY INCENTIVE PLAN

Dated: April 19, 2026

This Agreement amends the Celldex Therapeutics, Inc.

2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set

forth in the Plan.

R E C I T A L S

WHEREAS, Section 17.2 of the Plan reserves

to the Board of Directors (“Board”) of Celldex Therapeutics, Inc. (the “Company”) the right

to amend the Plan from time to time; and

WHEREAS, the Board desires to amend the Plan to

increase the number of shares available for awards under the plan by 3,400,000 shares in the manner hereinafter provided subject to approval

by the Company’s stockholders; and

WHEREAS, the Board desires to amend the Plan to

increase the limitation on outside director compensation under the Plan in the manner hereinafter provided.

NOW THEREFORE, the Plan is hereby amended as follows:

1. Amendment to Plan

Share Limitation.

Section 4.1(a) of the Plan

is amended and restated in its entirety as follows:

“(a) Subject to adjustment pursuant

to Section 4.3 and any other applicable provisions hereof, the maximum aggregate number of shares of Common Stock which may be issued

under all Awards granted to Participants under the Plan shall be (i) 12,900,000 shares plus (ii) such number of unused shares

of Common Stock reserved under the Prior Plan as of the Effective Date, which unused reserve shall be rolled into this Plan (subsections

(i) and (ii) together, the “Share Reserve”); all of which shares may, but need not, be issued in respect

of Incentive Stock Options. In addition, there shall be rolled into this Plan and added to the Share Reserve (but not issued in respect

of Incentive Stock Options) such number of shares of Common Stock subject to outstanding grants or awards under the Prior Plan as of the

Effective Date which are thereafter forfeited, cancelled or otherwise lapse in accordance with the provisions of Section 4.1(b).”

2. Amendment to Tax

Withholding Provision.

Section 16.5 of the Plan is

amended and restated in its entirety as follows:

16.5

Tax Withholding. The Company may require, as a condition to the grant, vesting, settlement, or delivery of any Award, the

satisfaction of applicable federal, state, local, and foreign tax withholding obligations. To satisfy such obligations, the Committee

is authorized, in its discretion and subject to applicable law, to (i) require cash payments by the Participant, (ii) withhold

from any amounts otherwise payable in cash to the Participant, (iii) withhold a number of whole shares otherwise issuable with respect

to the Award having an aggregate fair market value equal to the amount of such obligations, (iv) accept delivery by the Participant

to the Company of shares having an aggregate fair market value equal to the amount of such obligations, and/or (v) facilitate a sale

of shares issued upon settlement to generate proceeds sufficient to satisfy such obligations. Notwithstanding the foregoing, the number

of shares withheld pursuant to clause (iii) shall not exceed such number as is necessary to satisfy the maximum statutory tax rates

(or such lower rate as may be necessary to avoid adverse accounting treatment) in the Participant’s applicable jurisdictions. Shares

withheld or delivered to the Company pursuant to this section shall not again be available for issuance under the Plan. For purposes of

withholding, fair market value shall be determined pursuant to the Company’s consistently applied valuation method for tax withholding.

3. No Other Changes. Except

as set forth herein, the Plan shall remain in full force and effect without modification.

IN WITNESS WHEREOF, the undersigned, a duly authorized

officer of the Company, has executed this Amendment as of the date first above written as evidence of its adoption by the Company.

CELLDEX THERAPEUTICS, INC.

By: /s/ Sam Martin

Name: Sam Martin

Title: Senior Vice President and Chief Financial Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 25, 2026

Entity File Number

000-15006

Entity Registrant Name

Celldex

Therapeutics, Inc.

Entity Central Index Key

0000744218

Entity Tax Identification Number

13-3191702

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Perryville III Building, 53 Frontage Road, Suite 220

Entity Address, City or Town

Hampton

Entity Address, State or Province

Entity Address, Postal Zip Code

08827

City Area Code

908

Local Phone Number

200-7500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $.001

Trading Symbol

CLDX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration